Chiesi Pharmaceuticals GmbH (formerly Torrex Chiesi Pharma GmbH) is a 100% subsidiary of the Italian family-owned company Chiesi Farmaceutici S.p.A. and is divided into three different business units.
The Chiesi Austria business unit is responsible for the local business, while the Multi-Country Organization (MCO), together with partners, oversees sales and marketing in the Baltic, Balkan and CIS regions. Six wholly owned subsidiaries (Bulgaria, Romania, Hungary, Slovenia, Slovakia and the Czech Republic) report to the CEE hub, which is also located in Vienna.
The Chiesi Group is an international, research-oriented pharmaceutical and health company with headquarters in Parma, Italy. The company has over 85 years of experience and employs more than 6,000 people in 30 countries. Chiesi researches, develops and markets innovative drugs in its three therapeutic areas: (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support special care and consumer-facing self-care).
Chiesi, since 2019, is the world’s largest B Corp certified pharmaceutical group. Chiesi Farmaceutici S.p.A. has changed in 2018 its legal status to a Benefit Corporation, by incorporating a double purpose for the creation of shared value, and to generate value for its business, for society and the environment. The global B Corp movement promotes business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to include objectives of common benefit in its bylaws and to report annually in a transparent way. The Group is committed to becoming carbon neutral by the end of 2035.
For further information: www.chiesi.com